Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies

NCT ID: NCT02499861

Last Updated: 2017-11-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2017-10-24

Brief Summary

This Phase I/IIa study will test the combination of the epigenetic drug decitabine with the isoflavone genistein in children with leukemias and solid tumors. For the phase I study, the maximum tolerated dose will be evaluated in pediatric patients with relapsed or refractory leukemia and solid tumors. For the phase II study, only patients with relapsed or refractory leukemias will be included. To further evaluate the treatment efficacy and gain further insight into action of these drugs, the DNA methylation levels before and after treatment for all participants, pharmacokinetics parameters such as through level for decitabine and through and peak level for genistein will be measured. Pharmacogenomics testing for decitabine will be performed prior to cycle 1 of treatment.

Decitabine will be administered over a 24 hours infusion on day 1 of cycle (28 days) and genistein will be taken orally twice daily from day 2 to 21, followed by a 7 days rest period.

Conditions

Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Decitabine and Genistein

continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.

Group Type: EXPERIMENTAL

Decitabine and Genistein

Intervention Type: DRUG

intravenous Decitabine with oral genistein

Interventions

Decitabine and Genistein

intravenous Decitabine with oral genistein

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age ≥ 2 years of age and < 21 years of age at time of study enrollment
• Able to swallow genistein or take it with a puree.
• Patients must have a diagnosis of recurrent or refractory solid tumors, including Central Nervous System tumors, lymphoma or leukemia for which standard curative measures do not exist or are no longer effective
• For solid tumors, patients must have either measurable or evaluable disease. For leukemia, patients must have > 5% blasts in the bone marrow.
• Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy.
• Performance level: Karnofsky ≥50% for patients ≥ 16 years of age or Lansky ≥ 50% for patients < 16 years of age
• Life expectancy at least one month
• Patients must have adequate bone-marrow function
• Patients must have normal organ as defined below: (total bilirubin ≤ 24microM/L), Amylase/pancreatic amylase≤1.5 × institutional upper limit of normal, Aspartate Aminotransferase (AST) /Alanine Aminotransferase (ALT) ≤2.5 × institutional upper limit of normal, creatinine clearance ≥60 mL/min/1.73 m2.

OR creatinine according to age/gender

• Nervous system disorders (CTCAE v4) resulting from prior therapy must be ≤ Grade 2
• Participants of child-bearing potential and men must agree to use adequate contraception for the duration of study treatment, and 4 months after completion of decitabine and genistein administration.
• All patients and/or their parents or legally authorized representatives must sign a written informed consent

Exclusion Criteria

• Prior decitabine or genistein therapy.
• Patients who are receiving any other investigational agents.
• Nasogastric or gastrostomy (or equivalent) administration of genistein is not allowed.
• Patients with known exclusive non-measurable leptomeningeal disease at enrolment should be excluded from this clinical trial.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine and genistein.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (receiving antibiotics), symptomatic heart or lung disease, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or breast-feeding women are excluded from this study. All girls of child bearing potential must have a negative pregnant test prior to enrolment.
• Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

St. Justine's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Henrique Bittencourt, MD, PhD

Pediatric Hematologist-Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Henrique Bittencourt, MD

Role: PRINCIPAL_INVESTIGATOR

St. Justine's Hospital

Locations

St. Justine's Hospital

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

DEC-GEN001

Identifier Type: -

Identifier Source: org_study_id